索利那新联合依帕司他治疗2型糖尿病合并膀胱过度活动症的疗效观察

Effect of Solifenacin and Epalrestat combination therapy on type 2 diabetes complicated with overactive bladder

目的观察索利那新联合依帕司他治疗T2DM合并膀胱过度活动症(OAB)的疗效和安全性。方法选取T2DM合并OAB患者80例,随机分为对照组(Con)24例,依帕司他组29例,索利那新+依帕司他组27例。Con组予常规膀胱训练、降糖、降压、调脂、营养神经等一般治疗。在一般治疗的基础上,依帕司他组口服依帕司他50 mg,3次/d。索利那新+依帕司他组口服索利那新5 mg,1次/d,依帕司他50 mg,3次/d。观察12周,记录排尿日记、OAB自我评价量表(OABSS)评分、最大尿流率(Qmax)、平均尿流率(Qave)、排尿量(VV)。结果索利那新+依帕司他组治疗后24 h排尿次数、夜尿次数、尿急次数、尿失禁次数、OABSS评分均低于Con组和依帕司他组,Qmax、Qave、VV高于Con组和依帕司他组(P<0.05);依帕司他组治疗后OABSS评分低于Con组,VV高于Con组(P<0.05);索利那新+依帕司他组总有效率高于依帕司他组和Con组(92.6%vs69.0%vs41.7%,P<0.05)。结论索利那新联合依帕司他治疗T2DM合并OAB的疗效确切。

Objective To investigate the effect of solifenacin and epalrestat combination therapy on type 2 diabetes complicated with overactive bladder （OAB）. Methods A total of 80 patients with T2DM and OAB were randomly divided into three groups： control group （Con group, n=24）, epalrestat group （n = 29）, and solifenacin combines epalrestat group （n = 27）. Con group was treated with conventional therapy such as routine bladder training, anti-hyperglycemic, anti-hypertensive, lipid lowering treatment,and nerve nutrition. Epalrestat group was treated with epalrestat 50 rag,3/d orally on the basis of conventional treatment. Solifenacin group was treated with solifenacin 5 rag, l/d, and epalrestat 50 rag, 3/d orally. All the subjects were followed up for 12 weeks. Voiding diary, OAB self rating scale （OABSS） score,maximum urinary flow rate （Qraax）,average urinary flow rate （Qave）,and urine volume（W） were recorded. Results The daily raieturition frequency in 24h, times of nocturia, urgency, frequency, and urinary incontinence, and OABSS scores were lower, while Qmax, Qave, and W were higher in solifenacin group than in Con group and epalrestat group （P〈0.05）. The OABSS scores were lower while W was higher in epalrestat group than in Con group （P〈0.05）. The total effective rate was higher in solifenacin group than in Con group and epalrestat group （ 92.6 % vs 69 % vs 41.7 %, P 〈 0. 05 ）. Conclusion Solifenacin and epalrestat combination therapy was effective in treating patients with T2DM and OAB.